Trajectory and early predictors of apathy development in first-episode psychosis and healthy controls: a 10-year follow-up study.


Journal

European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 23 09 2019
accepted: 08 02 2020
pubmed: 5 3 2020
medline: 4 6 2021
entrez: 5 3 2020
Statut: ppublish

Résumé

Apathy is prevalent in first-episode psychosis (FEP) and associated with reduced global functioning. Investigations of the trajectory of apathy and its early predictors are needed to develop new treatment interventions. We here measured the levels of apathy over the first 10 years of treatment in FEP and in healthy controls (HC). We recruited 198 HC and 198 FEP participants. We measured apathy with the Apathy Evaluation Scale, self-report version, psychotic symptoms with the Positive and Negative Syndrome Scale, depression with the Calgary Depression Scale for Schizophrenia, functioning with the Global Assessment of Functioning Scale, and also estimated the duration of untreated psychosis (DUP). The longitudinal development of apathy and its predictors were explored using linear mixed models analyses. Associations to functioning at 10 years were investigated using multiple hierarchical linear regression analyses. In HC, mean apathy levels were low and stable. In FEP, apathy levels decreased significantly during the first year of treatment, followed by long-term stability. High individual levels of apathy at baseline were associated with higher apathy levels during the follow-up. Long DUP and high baseline levels of depression predicted higher apathy levels at follow-ups. The effect of DUP was persistent, while the effect of baseline depression decreased over time. At 10 years, apathy was statistically significantly associated with reduced functioning. The early phase of the disorder may be critical to the development of apathy in FEP.

Identifiants

pubmed: 32130475
doi: 10.1007/s00406-020-01112-3
pii: 10.1007/s00406-020-01112-3
pmc: PMC7423800
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

709-722

Subventions

Organisme : Helse Sør-Øst RHF
ID : #2006233
Organisme : Helse Sør-Øst RHF
ID : #2006258
Organisme : Helse Sør-Øst RHF
ID : #2011085
Organisme : Helse Sør-Øst RHF
ID : #2014102
Organisme : Helse Sør-Øst RHF
ID : #2015088
Organisme : Norges Forskningsråd
ID : 223273/F50
Organisme : Stiftelsen Kristian Gerhard Jebsen
ID : SKGJ-MED-008

Références

Am J Psychiatry. 2012 Apr;169(4):374-80
pubmed: 22407080
Psychiatry Res. 2017 Jan;247:1-5
pubmed: 27863311
Psychiatry Res. 1991 Aug;38(2):143-62
pubmed: 1754629
Schizophr Res. 2012 Dec;142(1-3):12-9
pubmed: 23025994
Compr Psychiatry. 2012 Apr;53(3):292-8
pubmed: 21632038
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Early Interv Psychiatry. 2018 Aug;12(4):561-571
pubmed: 29076240
Arch Gen Psychiatry. 2004 Mar;61(3):310-7
pubmed: 14993119
Psychopathology. 2011;44(6):345-53
pubmed: 21847001
Eur Psychiatry. 2008 Jan;23(1):33-9
pubmed: 18029152
Schizophr Res. 2001 Aug 1;51(1):39-46
pubmed: 11479064
Br J Psychiatry. 2017 May;210(5):324-332
pubmed: 28302699
Schizophr Res. 2018 Mar;193:173-181
pubmed: 28648915
Psychiatry Res. 2017 Jul;253:240-248
pubmed: 28395229
BMC Public Health. 2012 Oct 29;12:918
pubmed: 23107281
Schizophr Bull. 2017 Mar 1;43(2):240-244
pubmed: 27421793
Schizophr Res. 2012 May;137(1-3):246-50
pubmed: 22356801
Schizophr Res. 2007 Feb;90(1-3):255-7
pubmed: 17178214
Br J Psychiatry Suppl. 1998;172(33):53-9
pubmed: 9764127
Schizophr Bull. 2015 Jul;41(4):892-9
pubmed: 25528757
Schizophr Res. 2015 Oct;168(1-2):84-91
pubmed: 26265299
Schizophr Res. 2017 Nov;189:84-90
pubmed: 28185786
Eur Neuropsychopharmacol. 2014 May;24(5):693-709
pubmed: 24275699
J Nerv Ment Dis. 2015 May;203(5):387-92
pubmed: 25919385
Eur Psychiatry. 2012 May;27(4):240-4
pubmed: 21292455
Psychol Med. 2011 Jul;41(7):1461-9
pubmed: 20942996
World Psychiatry. 2017 Feb;16(1):14-24
pubmed: 28127915
Psychiatry Res. 1998 Jun 15;79(2):163-73
pubmed: 9705054
Clin Psychol Rev. 2011 Feb;31(1):161-8
pubmed: 20889248
Schizophr Res. 2012 Apr;136(1-3):19-24
pubmed: 22285655
Schizophr Res. 2003 Sep 1;63(1-2):79-88
pubmed: 12892861
Schizophr Res. 2014 Jun;156(1):107-14
pubmed: 24794879
Schizophr Bull. 1982;8(3):470-84
pubmed: 7134891
J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):243-54
pubmed: 1821241
Schizophr Bull. 2006 Oct;32(4):609-13
pubmed: 16914639
Schizophr Res. 2015 Dec;169(1-3):418-422
pubmed: 26386901
Schizophr Bull. 2019 Apr 25;45(3):610-619
pubmed: 30124959
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
J Nerv Ment Dis. 2015 May;203(5):379-86
pubmed: 25900547
Br J Psychiatry. 2004 Aug;185:108-15
pubmed: 15286061
Psychiatry Res. 2018 Sep;267:140-147
pubmed: 29906681
Acta Psychiatr Scand. 2018 May;137(5):380-390
pubmed: 29532909
PLoS One. 2017 Nov 2;12(11):e0187141
pubmed: 29095875
Arch Gen Psychiatry. 2008 Jun;65(6):634-40
pubmed: 18519821
JAMA. 1994 Dec 14;272(22):1749-56
pubmed: 7966923
Schizophr Res. 2010 Jan;116(1):20-6
pubmed: 19948392
Br J Psychiatry. 2009 Jan;194(1):18-24
pubmed: 19118320
Schizophr Bull. 2010 Mar;36(2):359-69
pubmed: 18644851
Arch Gen Psychiatry. 2004 Feb;61(2):143-50
pubmed: 14757590
Schizophr Res. 2016 Apr;172(1-3):23-8
pubmed: 26947210
Schizophr Res. 2015 Aug;166(1-3):9-16
pubmed: 25982811
Schizophr Res. 2017 Aug;186:29-38
pubmed: 27230288
J Psychiatr Res. 2013 Jun;47(6):718-25
pubmed: 23472837
Acta Psychiatr Scand. 2014 Oct;130(4):290-9
pubmed: 24850369
Eur Addict Res. 2005;11(1):22-31
pubmed: 15608468
Psychiatr Serv. 2009 Nov;60(11):1495-503
pubmed: 19880468
Schizophr Res. 2011 Oct;132(1):24-7
pubmed: 21771567
Schizophr Res. 2011 Dec;133(1-3):22-8
pubmed: 21968080
Schizophr Res. 2019 Apr;206:355-361
pubmed: 30482643
J Psychiatr Res. 2000 Jan-Feb;34(1):11-3
pubmed: 10696828
Neuropsychologia. 2018 Sep;118(Pt B):22-33
pubmed: 28966139
Schizophr Res. 1996 May;19(2-3):213-9
pubmed: 8789920
Psychol Med. 2008 Sep;38(9):1241-9
pubmed: 18070373
J Psychopharmacol. 2015 Feb;29(2):116-26
pubmed: 25516370
Eur Arch Psychiatry Clin Neurosci. 2016 Aug;266(5):387-96
pubmed: 27107764
J Affect Disord. 2012 Sep;140(1):38-47
pubmed: 22099566
Biol Psychiatry. 1999 Oct 1;46(7):899-907
pubmed: 10509173
Schizophr Res. 1992 Mar;6(3):201-8
pubmed: 1571313
Psychol Med. 2014 Jun;44(8):1577-90
pubmed: 24067164
Schizophr Res. 2017 Aug;186:39-45
pubmed: 27453425
Psychol Med. 2015 Jun;45(8):1613-27
pubmed: 25425086
J Clin Psychiatry. 2014;75 Suppl 1:3-7
pubmed: 24581452
Schizophr Res. 2011 Dec;133(1-3):193-8
pubmed: 21788116
Aust N Z J Psychiatry. 2019 Nov;53(11):1080-1092
pubmed: 30722671
Schizophr Res. 2008 Oct;105(1-3):95-104
pubmed: 18715756

Auteurs

Siv Hege Lyngstad (SH)

NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway. s.h.lyngstad@medisin.uio.no.

Erlend Strand Gardsjord (ES)

Division of Mental Health and Addiction, Nydalen DPS, Oslo University Hospital, Oslo, Norway.

Magnus Johan Engen (MJ)

NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Beathe Haatveit (B)

NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Henrik Myhre Ihler (HM)

NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Kirsten Wedervang-Resell (K)

NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Psychiatric Research and Development, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Carmen Simonsen (C)

Division of Mental Health and Addiction, Early Intervention in Psychosis Advisory Unit for South East Norway, Oslo University Hospital, Oslo, Norway.

Ingrid Melle (I)

NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Ann Færden (A)

Division of Mental Health and Addiction, Department of Acute Psychiatry, Oslo University Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH